Meeting Abstracts and Posters | Publications | CG Oncology

Skip to main content

Meeting Abstracts and Posters

ASCO 2022
Meeting Abstract

CORE-002, Phase 1b/2 CG0070 plus nivolumab combo in MIBC demonstrated 54% Pathological Complete Response Rate

ASCO 2022
Meeting Abstract

CORE-001, Phase 2 CG0070 plus pembrolizumab combo in NMIBC demonstrated 92% Complete Response Rate at Any Time

ASCO GU 2022
Meeting Abstract

BOND-003, Phase 3 CG0070 monotherapy pivotal trial in BCG-unresponsive NMIBC

AACR 2022
Meeting Abstract

CORE-001, Phase 2 CG0070 plus pembrolizumab combo in NMIBC demonstrated 100% Complete Response Rate at 3 Months in 10 patients.

SITC 2021
Poster

CORE-001, Phase 2 CG0070 plus pembrolizumab combo in NMIBC demonstrated 100% Complete Response Rate at 3 Months in 7 patients (pdf)

SITC 2021
Poster

BOND-003, Phase 3 CG0070 monotherapy pivotal trial in BCG-unresponsive NMIBC (pdf)

AUA 2021
Meeting Abstract

CORE-001, Phase 2 CG0070 plus pembrolizumab combo in NMIBC demonstrated 100% Complete Response Rate at 3 Months in 5 patients (pdf)

SUO 2020
Poster

BOND-003, Phase 3 CG0070 monotherapy pivotal trial in BCG-unresponsive NMIBC (pdf)

SUO 2018
Meeting Abstract

BOND-002, Phase 2 CG0070 monotherapy trial in BCG-unresponsive NMIBC reporting 18-month follow-up (pdf)

2018 AUA
Meeting Abstract

BOND-002, Phase 2 CG0070 monotherapy trial in BCG-unresponsive NMIBC Interim Analysis of 12-month Results (pdf)

2017 AUA
Meeting Abstract

BOND-002, Phase 2 CG0070 monotherapy trial in BCG-unresponsive NMIBC Demonstrated 6-month Complete Response Rate of 44% in Interim Analysis (pdf)

ASCO 2012
Meeting Abstract

V0046, First in Human Phase 1 CG0070 Monotherapy trial in NMIBC Demonstrating Promising Efficacy and Tolerable Safety Profile in 35 Patients.

Publications

Phase 2 CG 00700 Safety and Efficacy Study
Interim results: Overall 6-month CR was 47% and patients with pure T1 showed a CR at 6 months (pdf)

Urologic Oncology 2017

Oncolytic viruses are novel immunotherapeutic agents with a two-pronged approach (pdf)

Frontiers in Oncology 2014

CG0070 Phase 1 safety and efficacy study of a GM-CSF-expressing oncolytic virus in BCG unresponsive NMIBC (pdf)

Journal of Urology 2012

CG0070 Phase 1 dose-escalation study (pdf)

Molecular Therapy 2006

CG0070, a Conditionally Replicating Granulocyte Macrophage Colony-Stimulating Factor-Armed Oncolytic Adenovirus for the Treatment of Bladder Cancer (pdf)

Cancer Therapy 2006

An Oncolytic Adenovirus (CG0070) selective for Retinoblastoma tumor suppressor Protein pathway-defective tumors (pdf)

Cancer Research 2003